Galicia lidera el debate sobre la rentabilidad social y económica de apostar por la inversión en ciencia

by Noso Capital

Organizado por Unirisco y Bio&Tech Smart Capital de Noso Capital, el evento pretende impulsar la inversión en transferencia del conocimiento y proyectos disruptivos y poner en valor su relevancia par...

Read more

Ysios Capital joins Neurona 120MUSD financing

by Ysios Capital

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of ...

Read more

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

by Inveready Asset Management

Thanks to the continued support of Inveready and Sodena, Palobiofarma has become the start-up with the broadest clinical pipeline in Spain, financed basically through licensing agreements such as the ...

Read more

Healthcare startups in Catalonia raise €220 million in 2023, despite global context

by Biocat

Venture capital remains the main source of investment for startups and scaleups, with €114 million (52%). This figure is down from the previous year, mainly due to the cautiousness of financial envi...

Read more

BeAble Capital y BBVA Research presentan el primer informe europeo sobre inversión en tecnologías Deep Science

by BeAble Capital

BeAble Capital, gestora de fondos de capital privado especializada en Science Equity: inversión en tecnologías Deep Science en fases pre-seed, seed y early stage, y BBVA Research, todo un referente ...

Read more

King & Wood Mallesons advises Tressis on the launch of its private equity fund Plan Capital Privado Global FCR

by Addleshaw Goddard

Plan Capital Privado Global FCR will invest around 30% in infrastructure funds, with exposure to mature assets providing essential services to local communities. The remaining 70% will be spread acros...

Read more

El capital privado encuentra en Galicia oportunidades de alto valor para invertir en ciencia y tecnología

by Noso Capital

Un centenar de inversores en ciencia y tecnología nacionales analizaron estas oportunidades en la primera sesión de Invertir en Ciencia sí es rentable, que se celebra en la Facultad de Medicina de ...

Read more

Oncostellae, Marina de Empresas e Ignicia, I Premio 'Invertir en ciencia sí es rentable' por su aportación a la innovación e impulsar ecosistemas de emprendimiento

by Noso Capital

La empresa gallega Oncostellae, el programa Ignicia promovido por la Xunta de Galicia y el ecosistema emprendedor Marina de Empresas-Lanzadera, recibieron hoy los premios Invertir en ciencia sí es re...

Read more

ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by Columbus Venture Partners

ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1...

Read more

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received 'Orphan Drug Designation' by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Inveready Asset Management

Palobiofarma S.L., backed by Inveready, is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Wi...

Read more

Invivo Partners is preparing to launch a €100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences

by Invivo Capital

Invivo Ventures III is strategically designed to propel the emergent field of synthetic biology, a domain where Invivo has already established a formidable presence through investments in pioneering c...

Read more

AbilityPharma announces a €7M investment from a European-Canadian syndicate of life sciences investors, including CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent and CDTI Innvierte

by Inveready Asset Management

The Catalan biopharmaceutical company Ability Pharmaceuticals, SA (AbilityPharma), focused on the development of innovative oral autophagy-inducing anticancer compounds, announces a €7M investment f...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Inbergune Capital Partners, participada ...

by Moira Capital Partners

Inbergune ha decidido crear un fondo enfocado en biotecnología, dos a...

Photos Stream